Trade Paratek Pharma - PRTK CFD

Add to favourite

2.22

2.3%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.05

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	2.17
Open	2.17
1-Year Change	-12.15%
Day's Range	2.17 - 2.22

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Sep 20, 2023	2.22	0.05	2.30%	2.17	2.22	2.17
Sep 19, 2023	2.17	0.00	0.00%	2.17	2.17	2.16
Sep 18, 2023	2.16	-0.01	-0.46%	2.17	2.18	2.16
Sep 15, 2023	2.17	-0.01	-0.46%	2.18	2.18	2.16
Sep 14, 2023	2.17	-0.01	-0.46%	2.18	2.18	2.17
Sep 13, 2023	2.18	-0.01	-0.46%	2.19	2.19	2.18
Sep 12, 2023	2.19	0.00	0.00%	2.19	2.19	2.19
Sep 11, 2023	2.18	-0.01	-0.46%	2.19	2.20	2.18
Sep 8, 2023	2.19	0.01	0.46%	2.18	2.19	2.18
Sep 7, 2023	2.19	0.01	0.46%	2.18	2.19	2.18
Sep 6, 2023	2.18	0.01	0.46%	2.17	2.19	2.17
Sep 5, 2023	2.18	0.01	0.46%	2.17	2.19	2.17
Sep 1, 2023	2.17	-0.02	-0.91%	2.19	2.20	2.17
Aug 31, 2023	2.19	0.02	0.92%	2.17	2.19	2.17
Aug 30, 2023	2.18	0.01	0.46%	2.17	2.20	2.17
Aug 29, 2023	2.18	0.01	0.46%	2.17	2.18	2.17
Aug 28, 2023	2.17	0.01	0.46%	2.16	2.18	2.16
Aug 25, 2023	2.18	0.01	0.46%	2.17	2.19	2.17
Aug 24, 2023	2.18	0.02	0.93%	2.16	2.18	2.16
Aug 23, 2023	2.16	0.00	0.00%	2.16	2.16	2.16

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Paratek Pharma Company profile

About Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Paratek Pharmaceuticals Inc revenues increased from $46.9M to $130.2M. Net loss decreased 39% to $59.1M. Revenues reflect Product revenue, net increase from $38.8M to $106.1M, Collaboration and royalty revenue increase from $1.5M to $8.2M, Government contract grant revenue increase from $3.4M to $9.2M. Lower net loss reflects Interest Expense decrease of 14% to $17.4M (expense).

Equity composition

Common Stock $.001 Par, 3/11, 100M auth., 13,467,933 issd. Insiders control 9.22%. IPO: 5/06 .3M shs. @ $6.50 per share by Bear, Stearns & Co. Inc. 02/09, Name changed from Novacea, Inc. 02/09, 5-for-1 reverse stock split. 10/14,1-for-12 reverse stock split.

Industry:

Pharmaceuticals (NEC)

75 Park Plaza
4th Floor
BOSTON
MASSACHUSETTS 02116
US